We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
DiaMedica Therapeutics Inc | NASDAQ:DMAC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.37 | 14.07% | 3.00 | 3.00 | 3.20 | 3.05 | 2.65 | 2.65 | 102,677 | 23:08:24 |
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders, is pleased to announce that Rick Pauls, President and CEO of DiaMedica, will participate in a fireside chat and host one-on-one meetings with investors at the Piper Sandler 32nd Annual Virtual Growth Conference. The fireside chat will be available on the Piper Sandler Conference website to registered attendees on November 23rd at 10:00 AM ET to December 3, 2020.
The Company will host the one-on-one meetings with investors on Tuesday, December 1, 2020, meetings can be requested exclusively via Piper Sandler.
A replay of the fireside chat can be accessed under Events and Presentations in the Investors section of our website at https://ir.diamedica.com/events-and-presentations
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”
For more information, please visit www.diamedica.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005186/en/
Scott Kellen Chief Financial Officer Phone: (763) 496-5118 skellen@diamedica.com
1 Year DiaMedica Therapeutics Chart |
1 Month DiaMedica Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions